In‐house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH‐related peptides

Abstract

Matrix effect and sample pretreatment significantly affect the percentage recovery of peptides in biological matrices, affecting the method robustness and accuracy. To counteract this effect, an internal standard (IS) is used; however, in most cases this is not available, which limits the analytical method. It is important to identify short peptides that can be used as ISs in the quantification of peptides in biological matrices. In this study, doping peptides GHRP‐4, GHRP‐5, GHRP‐6, Sermorelin (1–11), Sermorelin (13–20) and Sermorelin (22–29) were synthesized using solid‐phase peptide synthesis. Treatment with human blood, trypsin and chymotrypsin was used to determine the stability of the peptides. Products were evaluated using the high‐performance liquid chromatography‐diode array detector (HPLC‐DAD) method. The analytical methodology and sample pretreatment were effective for the analysis of these molecules. A unique profile related to protein binding and enzymatic stability of each peptide was established. GHRP‐4, GHRP‐6 and Sermorelin (22–29) can be considered as in‐house ISs as they were stable to enzyme and blood treatment and can be used for the quantification of peptides in biological samples. Peptides GHRP‐6 and Sermorelin (22–29) were used to analyse a dimeric peptide (26[F] LfcinB (20–30)2) in four different matrices to test these peptides as in‐house IS.